STOCK TITAN

Lexicon Pharmaceuticals (LXRX) director receives new option and RSU grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lexicon Pharmaceuticals director Raymond Debbane received new equity awards. On May 1, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring in 2036.

The option vests in three equal annual installments on each of the first three anniversaries of the grant date. He also received 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.

Positive

  • None.

Negative

  • None.
Insider DEBBANE RAYMOND
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Units 35,714 $0.00 --
Grant/Award Stock Option (Right to Buy) 43,478 $0.00 --
Holdings After Transaction: Restricted Stock Units — 35,714 shares (Direct, null); Stock Option (Right to Buy) — 43,478 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.
Option grant size 43,478 shares Stock option grant on May 1, 2026
Option exercise price $1.61 per share Exercise price for granted stock options
Option expiration May 1, 2036 Expiration date of stock options
RSU grant size 35,714 units Restricted Stock Unit grant on May 1, 2026
RSU vesting 100% after 1 year All RSUs vest on first anniversary of grant date
Post-grant option holdings 43,478 options Total option-related derivative position after transaction
Post-grant RSU holdings 35,714 RSUs Total RSU derivative position after transaction
Restricted Stock Units financial
"The director received 35,714 restricted stock units, which vest in full on the first anniversary"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"He was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"stock options for 43,478 shares of common stock at an exercise price of $1.61 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests in three equal annual installments on each of the first three anniversaries"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DEBBANE RAYMOND

(Last)(First)(Middle)
2445 TECHNOLOGY FOREST BLVD.
11TH FLOOR

(Street)
THE WOODLANDS TEXAS 77381

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$005/01/2026A35,714 (1) (2)Common Stock35,714$035,714D
Stock Option (Right to Buy)$1.6105/01/2026A43,478 (3)05/01/2036Common Stock43,478$043,478D
Explanation of Responses:
1. Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
2. Each restricted stock unit represents a contingent right to receive one share of common stock.
3. Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.
/s/ Raymond Debbane05/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Lexicon Pharmaceuticals (LXRX) director Raymond Debbane receive?

Raymond Debbane received stock options and restricted stock units as equity compensation. He was granted options on 43,478 shares at a $1.61 exercise price and 35,714 restricted stock units, each convertible into one share of common stock, subject to vesting conditions.

How do the new stock options for LXRX director Raymond Debbane vest?

The granted stock options vest over three years in equal portions. One third of the 43,478 option shares vest on each of the first three anniversaries of the May 1 grant date, aligning Debbane’s long-term incentives with Lexicon Pharmaceuticals’ performance over time.

What are the terms of the restricted stock units granted to the LXRX director?

The director received 35,714 restricted stock units that vest in a single tranche. All RSUs vest on the first anniversary of the May 1 grant date, and each unit represents a contingent right to receive one share of Lexicon Pharmaceuticals common stock upon vesting.

Did Raymond Debbane buy or sell Lexicon Pharmaceuticals (LXRX) shares in this Form 4?

The Form 4 reports equity awards, not open-market trades. Raymond Debbane acquired options and restricted stock units as a grant or award, with no reported purchases or sales of common shares for cash in this filing, indicating compensation-related transactions only.

What is the exercise price and expiration date of the LXRX stock options granted?

The granted stock options have an exercise price of $1.61 per share, fixing the cost to acquire common stock. These options expire in 2036, providing a long-dated window for potential exercise after vesting, consistent with typical long-term director compensation structures.